The federal clinical guidelines on “The diagnostics and treatment of uveitis associated with juvenile idiopathic arthritis”

Катаргина, Л А; Brzheskiy, V.V.; Гусева, М. Р.; Денисова, Е. В.; Дроздова, Е. А.; Zhukova, Ol'ga Vladimirovna; Nikishina, Irina; Старикова, А. В.

doi:10.18821/1993-1859-2016-11-2-102-111

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Препаратом выбора для лечения ЮИА-ассоциированных увеитов является МТ [52,53]. В случае недостаточной эффективности МТ, наблюдаемой у 20-30% пациентов с ЮИА-ассоциированных увеитов, рекомендуется применяются ГИБП, в первую очередь АДА или голимумаб [53][54][55]. Блокатор ко-стимуляции Т-лимфоцитов -абатацепт (АБЦ), рекомендуется пациентом, имеющим противопоказания для назначения ингибиторов ФНО-α.…”

Section: ювенильный идиопатический артритunclassified

Current approaches to treatment of uveitis in immune-mediated inflammatory rheumatic disease

Лисицына¹,

Alekberova²,

Давыдова

et al. 2020

Naučno-praktičeskaâ revmatologiâ

View full text Add to dashboard Cite

Non-infectious uveitis is the leading and insufficiently studied cause of irreversible decline in visual functions in patients with immune-mediated inflammatory rheumatic disease (IMIRDs). A multidisciplinary approach to the diagnosis and treatment of uveitis in patients with IMIRDs, involving close collaboration of rheumatologists and ophthalmologists, is the key factor for achieving favorable clinical outcomes. This article sheds light on current clinical, differential diagnostic and therapeutic challenges related to non-infectious uveitis in IMIDs-patients, with specific emphasis on state-of-the art approaches to therapy.

show abstract

Section: ювенильный идиопатический артритunclassified

Current approaches to treatment of uveitis in immune-mediated inflammatory rheumatic disease

Лисицына¹,

Alekberova²,

Давыдова

et al. 2020

Naučno-praktičeskaâ revmatologiâ

View full text Add to dashboard Cite

show abstract

Predicting the course of uveitis against the background of juvenile idiophatic arthritis when using topical therapy regimens. The results of mathematical modeling

Chasnyk,

Kononov,

Brzheskiy

et al. 2024

Ophthalmology Reports

View full text Add to dashboard Cite

BACKGROUND: Juvenile idiopathic arthritis is the most common rheumatic disease in children, and uveitis is its most destructive extra-articular manifestation. Despite the existence of Federal clinical guidelines for the management of these patients, their treatment is largely based on the experience of doctors and varies greatly even within the same country. AIM: The aim of the study is to find factors for predicting the course of uveitis and optimizing therapy. MATERIALS AND METHODS: The case histories of 150 children aged 1.5 to 17 years with active uveitis in the structure of juvenile arthritis were analyzed using multifactorial modeling (construction of classification trees). RESULTS: The fact of a significant influence of the time elapsed from the onset of rheumatic disease and uveitis until the start of therapy by genetically engineered medications (tumor necrosis factor alpha inhibitors) in treatment programs has been established. CONCLUSIONS: Thus, the inclusion of this factor into the group of controlling ones makes it possible to achieve inactive uveitis status after 1, 3, and 6 months in a higher percentage of cases. However, the obtained data still require additional clinical confirmation.

show abstract

Structure of corneal opacities in children in a specialized hospital practice

Mamakaeva

Pleskova

Катаргина

2021

Russian Pediatric Ophthalmology

View full text Add to dashboard Cite

AIM: To evaluate the nosological structure of various etiologies in a specialized pediatric ophthalmosurgical center for 5 years (from 2016 to 2020) MATERIAL AND METHODS: This prospective study was conducted at the Department of Eye Pathology in Children of the Helmholtz Moscow Research Institute of Eye Diseases from January 01, 2016, to December 31, 2020, and collected and summarized clinical observations in children with corneal opacity (CO) of various etiologies. Statistical annual reports and case histories of children who were hospitalized in the pediatric surgical department were analyzed. The analysis of discharge epicrisis was conducted only in children with corneal changes of various natures. RESULTS: The proportion of children with corneal opacities from 2016 to 2020 was 13.5% (954 children out of 7066 hospitalized). Secondary CO was determined in most cases and amounted to 75.2%. The leading nosologies were congenital corneal opacities (24.8%), post-traumatic changes (33.6%), and post-inflammatory corneal degenerations (37.1%). Penetrating keratoplasty was more often performed in congenital pathology (55.8%), and scarification was more often used in the group of children with postuveal CO (96.3%). CONCLUSION: Corneal opacities in children have a significant role in the overall structure of the visual organ pathology in children and have a large polymorphism. CO was secondary in the vast majority of children. Therefore, methods of CO prevention were searched. The general nosological structure did not undergo significant fluctuations throughout the study period.

show abstract

The federal clinical guidelines on “The diagnostics and treatment of uveitis associated with juvenile idiopathic arthritis”

Abstract: Federal clinical recommendations were approved at the presidium meeting of the All Russian Organization “Association of ophthalmologists” 24.09.2015

Cited by 3 publications

References 0 publications

Current approaches to treatment of uveitis in immune-mediated inflammatory rheumatic disease

Current approaches to treatment of uveitis in immune-mediated inflammatory rheumatic disease

Predicting the course of uveitis against the background of juvenile idiophatic arthritis when using topical therapy regimens. The results of mathematical modeling

Structure of corneal opacities in children in a specialized hospital practice

Contact Info

Product

Resources

About